

**CLAIMS**

1. Use of an IFN $\gamma$  neutralizing molecule for the manufacture of a medicament for preventing or treating a T1 inflammatory lung disease.
2. Use according to claim 1 wherein said T1 inflammatory lung disease is selected from the group consisting of COPD, emphysema, chronic bronchitis, bronchiolitis, severe asthma, sarcoidosis, berylliosis and cystic fibrosis.
3. Use according to claims 1-2, wherein said molecule is an anti-IFN $\gamma$  antibody or a fragment thereof.
4. Use according to claim 3, wherein said antibody is a monoclonal antibody.
5. Use according to claim 4, wherein said antibody is the antibody D9D10 or a fragment thereof.
6. Use according to claim 3, wherein said antibody is a humanized monoclonal antibody.
7. Use according to claim 6, wherein said antibody is a humanized D9D10 antibody.
8. Use of immunogenic IFN $\gamma$  for the manufacture of a medicament for preventing or treating a T1 inflammatory lung disease.
9. Use according to claim 8 wherein said T1 inflammatory lung disease is selected from the group consisting of COPD, emphysema, chronic bronchitis, bronchiolitis, severe asthma, sarcoidosis, berylliosis and cystic fibrosis.
10. Use according to claim 8, wherein immunogenic IFN $\gamma$  is a modified IFN $\gamma$ .
11. Use according to claim 10, wherein the IFN $\gamma$  protein is modified to immunogenic IFN $\gamma$  by crosslinking IFN $\gamma$  to an immunogenic non-self carrier protein.

12. Use according to claim 10, wherein the IFN $\gamma$  protein is modified to immunogenic IFN $\gamma$  by introducing at least one foreign T-cell epitope by insertion and/or substitution and/or addition and/or conjugation.
13. Use according to claim 8, wherein immunogenic IFN $\gamma$  is a non-self IFN $\gamma$  administered with or without adjuvant.
14. Use according to claim 8, wherein immunogenic IFN $\gamma$  is autologous IFN $\gamma$  in combination with an adjuvant.
15. Use of at least one autologous antigen presenting cell loaded with IFN $\gamma$  for the manufacture of a medicament for preventing or treating a T1 inflammatory lung disease.
16. Use according to claim 16, wherein the antigen presenting cell is a dendritic cell.